CD274 and neoplasm: Song et al. [51] investigated the efficacy of oxaliplatin and anti-PD-L1 agent in a murine CRC model, and they showed that when oxaliplatin was added to anti-PD-L1 drug, a statistically significant reduction in tumor growth was observed compared to oxaliplatin alone.